Introducing the Erigo®, a practical solution for the rehabilitation of patients with limited or no ability to walk, stand, or transfer. Designed for early-stage rehabilitation, Erigo offers a safe way to verticalize and mobilize patients, optionally supported by functional electrical stimulation.

A review of 22 studies involving 376 patients treated with Erigo showed promising results. Out of 7606 Erigo therapy sessions, there were only 30 reported side-effects/adverse events, resulting in a low event rate of 0.4%, with no severe adverse events noted.

This compares to conventional therapy methods, which reported a slightly higher event rate of 0.51% from 105 side-effects/adverse events across 20741 sessions, including 0.04% as severe adverse events. Yet, the largest difference is seen in comparison with conventional tilt table therapy.

Research involving 192 patients across 2749 conventional tilt table sessions reported a total event rate of 5.1%, with a notable significant increase in mild and moderate events compared to the 0.4% event rate with Erigo (p < 0.001).

Figure 1 presents the event ratio for each type of therapy, i.e. the percentage of therapy sessions in which an event occurred in relation to the total number of therapy sessions.

The Erigo system offers a safer, more efficient way to rehabilitate patients with limited mobility. The presented data highlights Erigo’s potential as a reliable early-stage rehabilitation tool. For further reading, you can find all references below and on our knowledge platform.

Figure 1: Event ratio (%) of mild, moderate and severe events in relation to total number of therapy sessions